Capricor Therapeutics price to free cash flow CAPR

Market value divided by free cash flow over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 33.9×; May 2023
Peer median: 9.4×

Capricor Therapeutics' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2023, at 33.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	33.9×	22.3×	37.9×
2022	21.6×	8.4×	25.4×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	130×	126×	203×
2014	9.5×	8.7×	13.4×

Against its peers

Companies in Drug Manufacturers - General nearest Capricor Therapeutics' size, closest first, today.

Company	Price to free cash flow
CAPRCapricor Therapeutics	n/m
ARVNArvinas	n/m
NATRNatures Sunshine Products	11.8×
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
Peer median	9.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Capricor Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.